数据
资源
版本对比
免费注册
预约演示
免费注册
Beckman Coulter
and
MeMed
to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between
Bacterial and Viral Infections
2023-01-31
·
BioSpace
引进/卖出
诊断试剂
Collaboration to Add
MeMed BV
to
Beckman Coulter
Test Menu for use on Access Family of Immunoassay Analyzers BREA, Calif. and HAIFA, Israel, Jan. 31, 2023 /PRNewswire/ --
Beckman Coulter Diagnostics
, a global leader in clinical diagnostics, and
MeMed
, a leader in the emerging field of advanced host-response technologies, announced today a strategic partnership to jointly develop and commercialize the proven
MeMed BV
® test, a host immune response diagnostic that is able to distinguish between
bacterial and viral infections
for use on the Access Family of Immunoassay Analyzers. Symptoms of
bacterial and viral infections
are often clinically indistinguishable, which creates challenges for physicians when deciding to start treating patients with antibiotics or not. Unfortunately, this ambiguity can result in the underuse and overuse of antibiotics. Studies have shown that underuse of antibiotics for patients with a
bacterial infection
can reach 20%.i While overuse of antibiotics contributes to antimicrobial resistance, which is one of the top 10 global public health threats according to the World Health Organization.ii Today,
antibiotic-resistant infections
account for more than 700,000 deaths globally with the potential to increase to 10 million deaths by the year 2025.iii The development of new antibiotics is almost at a standstill, critically accelerating the need for increased antibiotic stewardship.iii
MeMed BV
is a diagnostic test developed to address management of patients with acute infection in different clinical settings, including Emergency Departments. The
MeMed BV
test uses machine learning to integrate measurements of three key host-immune proteins (TRAIL,
IP-10
, and CRP) into a score indicating the likelihood of
bacterial or viral infections
. This performance has been validated on
MeMed
's compact immunoassay platform (
MeMed
Key®) by world class institutions in multi-national blinded validation studies as well as in real-world use, altogether in over 20,000 patients.
MeMed BV
on
MeMed
Key is US FDA cleared, CE-Marked and approved by the
Israeli Ministry of Health
. Under the terms of the agreement,
Beckman Coulter
has obtained the rights to develop and co-promote the proprietary
MeMed BV
test on its Access Family of Immunoassay Analyzers. "We are thrilled to be partnering with
MeMed
to make this novel test available to millions of patients through our Access Family of Immunoassay Analyzers. The ability to distinguish between
bacterial and viral infections
early in the diagnostic process has significant potential to impact patient care, as well as combat antimicrobial resistance," said Julie Sawyer Montgomery, President,
Beckman Coulter
. "Today's investment reflects our commitment to continuously expand our IA menu through novel biomarker development; advance Emergency Medicine diagnostics alongside our MDW biomarker to measure
infection
severity; and complement our microbiology innovations critical to identifying specific
bacterial infection
to optimize antibiotic therapies." Dr. Eran Eden,
MeMed
's CEO and co-founder, added: "Our vision for
MeMed BV
is that it becomes standard of care, enabling significant improvements in patient management to address the urgent global antimicrobial resistance threat. We believe that forging a strategic alliance with an industry leader, such as
Beckman Coulter
, will expedite the realization of this vision and support better clinical, operational, and financial outcomes for healthcare systems globally." About
Beckman Coulter
. Inc. A global leader in advanced diagnostics,
Beckman Coulter
has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services.
Beckman Coulter
is part of the
Danaher Corporation
family of global science and technology companies. Headquartered in Brea, Calif., it has more than 11,000 global team members. Follow and connect with
Beckman Coulter
via LinkedIn, Twitter, and Facebook About
MeMed
At
MeMed
, our mission is to translate the immune system's complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. Follow and connect with
MeMed
via LinkedIn, Twitter, and Facebook. © 2023
Beckman Coulter
. All rights reserved.
Beckman Coulter
, the stylized logo, and the
Beckman Coulter
product and service marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc.
in the United States and other countries.
MeMed
,
MeMed BV
, and
MeMed
Key are trademarks or registered trademarks of
MeMed
in the United States and other countries. Used under license. 2023-11271 i Craig JC, Williams GJ, Jones M, Codarini M, Macaskill P, Hayen A, et al. The accuracy of clinical symptoms and signs for the diagnosis of serious
bacterial infection
in young febrile children: Prospective cohort study of 15 781
febrile illnesses
. BMJ. 2010 Apr 20;340. ii No Time to Wait: Securing the Future From
Drug-Resistant Infections
, Report to the Secretary-General of the United Nations, April 2019, Interagency Coordination Group on Antimicrobial Resistance iii World Health Statistics 2022, Monitoring health for the Sustainable Development Goals, World Heal Organization, 2022
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Beckman Coulter, Inc.
MeMed Diagnostics Ltd.
Beckman Coulter Diagnostics Ltd.
[+2]
适应症
细菌感染
急性发热性疾病
抗生素耐药性感染
[+2]
靶点
CXCL10
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
2024年2月全球首批及特殊审评药物报告
智慧芽生物医药
TYK2抑制剂药物研发及专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务